Athira Pharma Faces Delisting Concerns

Ticker: LONA · Form: 8-K · Filed: Apr 16, 2025 · CIK: 1620463

Athira Pharma, INC. 8-K Filing Summary
FieldDetail
CompanyAthira Pharma, INC. (LONA)
Form Type8-K
Filed DateApr 16, 2025
Risk Levelhigh
Sentimentbearish

Sentiment: bearish

Topics: delisting, listing-standards, regulatory

TL;DR

Athira Pharma might be delisted - big trouble ahead.

AI Summary

Athira Pharma, Inc. has filed an 8-K report on April 15, 2025, indicating a notice of delisting or failure to satisfy a continued listing rule or standard. The company, formerly known as M3 Biotechnology, Inc., is based in Bothell, WA.

Why It Matters

This filing signals potential issues with Athira Pharma's continued listing on an exchange, which could impact its stock trading and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards is a severe event that can lead to significant stock price declines and operational challenges.

Key Players & Entities

FAQ

What specific listing rule or standard has Athira Pharma failed to satisfy?

The filing does not specify the exact rule or standard that Athira Pharma has failed to satisfy, only that a notice has been issued.

What is the potential impact of this notice on Athira Pharma's stock trading?

A notice of delisting or failure to meet listing standards can lead to increased volatility, potential trading halts, and a significant decline in stock price.

Has Athira Pharma provided any details on steps it plans to take to rectify the situation?

This specific 8-K filing does not contain information regarding Athira Pharma's plans to address the delisting concerns.

When was Athira Pharma, Inc. formerly known as?

Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc., with a date of name change on September 24, 2014.

What is the primary business of Athira Pharma, Inc. according to its SIC code?

According to its Standard Industrial Classification (SIC) code [2836], Athira Pharma, Inc. is involved in Biological Products (No Diagnostic Substances).

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 16, 2025 regarding Athira Pharma, Inc. (LONA).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing